Thomas Stiefel

This inventor holds 12 USPTO granted patents and 2 published patent applications, plus 5 CIPO patents and 6 EPO patents. Top assignees: Biosyn Arzneimittel Gmbh, Biosyn Arzeimittel Gmbh, Other. Active years: 1993-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Thomas Stiefel. Retrieved from https://idiyas.com/inventor/thomas-stiefel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 12 (Patent Applications = 2)

% Patents Active = 91.7

CIPO Patents = 5 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 5)

Average Co-Inventor Count = 2.7

ph-index = 2

Forward Citations = 14(Granted Patents)

Location History:

7000 Stuttgart 1, DE (1993)
70184 Stuttgart, DE (2006)
Stuttgart, DE (2003 - 2020)

Company Filing History:

8 out of 8

Biosyn Arzneimittel Gmbh

patents

1 out of 1

Biosyn Arzeimittel Gmbh

patent

3 out of 834,513

Other

patents

Years Active: 1993-2020

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10800820 - Preparation methods for a novel generation of biological safe KLH products used for cancer treatment, for the development of conjugated therapeutic vaccines and as challenging agents (2020-10-13),

2. 10221220 - Preparation methods for a novel generation of biological safe KLH products used for cancer treatment, for the development of conjugated therapeutic vaccines and as challenging agents (2019-03-05),

3. 9277761 - Nutrition trace element composition (2016-03-08),

4. 8636973 - Method of producing pharmacologically pure crystals (2014-01-28),

5. 7282578 - Nucleic acid molecule comprising a nucleic acid sequence which codes for a haemocyanin (2007-10-16),

6. 7273928 - Nucleic acid molecule comprising a nucleic acid sequence coding for a haemocyanin (2007-09-25),

7. 7265217 - Recombinant mistletoe lectin (2007-09-04),

8. 7125557 - Nucleic acid molecule comprising a nucleic acid sequence which codes for a haemocyanin, and comprising at least one intron sequence (2006-10-24),

9. 7125556 - Nucleic acid molecule comprising a nucleic acid sequence coding for a haemocyanin (2006-10-24),

10. 6927207 - Recombinant mistletoe lectines (2005-08-09),

11. 6656509 - Combination of selenium-containing compounds with cytostatics (2003-12-02),

12. 5231081 - Use of hemocyanins and arylphorins to influence the immune system and (1993-07-27),

Title: Thomas Stiefel: Innovator in Biologically Safe KLH Products

Introduction

Thomas Stiefel is a prominent inventor based in Stuttgart, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of biologically safe products for cancer treatment. With a total of 12 patents, his work has the potential to impact therapeutic vaccine development and cancer therapies.

Latest Patents

Stiefel's latest patents focus on preparation methods for a novel generation of biologically safe KLH (keyhole limpet hemocyanin) products. These innovations are aimed at enhancing cancer treatment and developing conjugated therapeutic vaccines. His inventions also include methods for producing virus-free hemocyanin, which is crucial for ensuring the safety and efficacy of these biological products.

Career Highlights

Throughout his career, Thomas Stiefel has worked with various organizations, including Biosyn Arzneimittel GmbH. His expertise in biotechnology and innovative approaches to product development have established him as a key figure in his field.

Collaborations

Stiefel has collaborated with notable professionals such as Jürgen Markl and Benjamin Altenhein. These partnerships have further enriched his research and development efforts, leading to advancements in the biotechnology sector.

Conclusion

Thomas Stiefel's contributions to the field of biotechnology, particularly through his patents on KLH products, demonstrate his commitment to advancing cancer treatment. His innovative methods and collaborations highlight the importance of research in developing safe and effective therapeutic solutions.

Profile summary based on public USPTO records.